Onward Medical N.V. (ONWRF)
| Market Cap | 140.37M -28.4% |
| Revenue (ttm) | 9.62M +210.1% |
| Net Income | -51.72M |
| EPS | -0.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 2.310 |
| Previous Close | 2.710 |
| Day's Range | 2.310 - 2.310 |
| 52-Week Range | 2.310 - 5.700 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Onward Medical
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven move... [Read more]
Financial Performance
In 2025, Onward Medical's revenue was 5.41 million, an increase of 211.33% compared to the previous year's 1.74 million. Losses were -41.79 million, 17.0% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Onward Medical Earnings Call Transcript: Q3 2026
Q3 revenue was €2.5M, with 88 ARC-EX systems sold or supplied via paid evaluation, up 120% YoY. Empower BP enrollment reached 31, keeping the spring 2027 interim analysis on track; reimbursement and VA evaluation timelines shifted some ARC-EX revenue into 2027.
Onward Medical Earnings release: Q3 2026
Onward Medical released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Onward Medical Slides: Q3 2026
Onward Medical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution
EINDHOVEN, the Netherlands, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026
EINDHOVEN, The Netherlands, Oct. 27, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies Fouad Azzam is a Partner with EQT...
Onward Medical Earnings Call Transcript: Q2 2026
Revenue surged 250% year-over-year to EUR 4.2 million, driven by rapid ARC-EX adoption in the U.S. and Europe, with strong home use demand and a 90%+ VA conversion rate. Cash position strengthened to EUR 81.5 million, supporting ongoing pivotal studies and commercialization.
Onward Medical Earnings release: Q2 2026
Onward Medical released its Q2 2026 earnings on September 9, 2026, summarizing the period's financial results.
Onward Medical Quarterly report: Q2 2026
Onward Medical has published its Q2 2026 quarterly earnings report on September 9, 2026.
Onward Medical Slides: Q2 2026
Onward Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 9, 2026.
ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026
EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
EINDHOVEN, the Netherlands, Sept. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to res...
Onward Medical Slides: Company presentation
Onward Medical has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Onward Medical Slides: Corporate presentation
Onward Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Onward Medical Earnings Call Transcript: Q1 2026
Q1 revenue reached EUR 2 million, driven by strong ARC-EX adoption in clinics and homes, with home units surpassing clinic units for the first time. A EUR 40 million equity raise extended the cash runway into Q1 2028, while clinical and commercial expansion continues in the U.S. and Europe.
Onward Medical Earnings release: Q1 2026
Onward Medical released its Q1 2026 earnings on May 26, 2026, summarizing the period's financial results.
Onward Medical Slides: Q1 2026
Onward Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 26, 2026.
ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones
EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functio...
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functio...
ONWARD Medical Publishes Closing of Bookbuild Offering
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions
EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
Onward Medical Earnings Call Transcript: H2 2025
Achieved rapid U.S. market penetration with 117 ARC-EX systems sold, EUR 5.4M in revenue, and major regulatory milestones. Raised over EUR 50M, advanced pivotal studies, and set the stage for accelerated growth and potential Nasdaq IPO.